Brigatinib and Edoxaban Tosylate
Determining the interaction of Brigatinib and Edoxaban Tosylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter 1 (OCT1), and/or multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K). The proposed mechanism, based on in vitro data, is decreased drug clearance due to brigatinib-mediated inhibition of these transport proteins. MANAGEMENT: Caution is advised if brigatinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OCT 1, MATE 1, and/or MATE 2K transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever brigatinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter 1 (OCT1), and/or multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K). The proposed mechanism, based on in vitro data, is decreased drug clearance due to brigatinib-mediated inhibition of these transport proteins.
MANAGEMENT: Caution is advised if brigatinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OCT 1, MATE 1, and/or MATE 2K transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever brigatinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: edoxaban
Brand name: Savaysa
Synonyms: Edoxaban
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Brigatinib-Edrophonium and Atropine
- Brigatinib-Edrophonium Injection
- Brigatinib-Edurant
- Brigatinib-EEMT
- Brigatinib-EEMT DS
- Brigatinib-EEMT HS
- Edoxaban Tosylate-Brilinta
- Edoxaban Tosylate-Brilinta Tablets
- Edoxaban Tosylate-Brimonidine
- Edoxaban Tosylate-Brimonidine and brinzolamide ophthalmic
- Edoxaban Tosylate-Brimonidine and Timolol
- Edoxaban Tosylate-Brimonidine and timolol ophthalmic